Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 12091424 Rapamycin derivatives

Patent 12091424 was granted and assigned to Novartis on September, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
Novartis
Novartis
0
Date Filed
October 12, 2021
0
Date of Patent
September 17, 2024
0
Patent Applicant
Novartis
Novartis
0
Patent Application Number
17499433
0
Patent Citations
‌
US Patent 9669032 Enhanced treatment regimens using mTOR inhibitors
0
‌
US Patent 8906374 Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors
0
‌
US Patent 9358236 Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases
0
‌
US Patent 9427463 Combination therapy with CD4 lymphocyte depletion and mTOR inhibitors
0
‌
US Patent 9683048 Antibody molecules to PD-1 and uses thereof
0
Patent Inventor Names
Tea Shavlakadze
0
Silvio Roggo
0
David Jonathan Glass
0
Andrew William Patterson
0
Michael Connolly
0
Manuel Mihalic
0
Simone Bonazzi
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
12091424
0
Patent Primary Examiner
‌
Po-Chih Chen
0

Find more entities like US Patent 12091424 Rapamycin derivatives

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo